Back to search results
NCT07634835

Transcranial Magnetic Stimulation for Adolescents and Young Adults With Cannabis Use Disorder

Not Yet Recruiting
NAAges 15–21InterventionalTreatment
University of Minnesota
~50 participants
Updated 2026-06-09 on ClinicalTrials.gov
What's tested:Magstim SuperRapid2Sham rTMS

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Feasibility, tolerability, and acceptability of rTMS
Measured over Month 4
+2 more outcomes measured

Conditions

Cannabis Use
Cannabis Use Disorder

Explore related trials

Cannabis Use Disorder

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Jazmin Camchong, PhD · PRINCIPAL_INVESTIGATOR · University of Minnesota

Who to contact

Jazmin Camchong, PhD
[email protected]
952-444-0137
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

15-21 years old
For minors, parent/legal guardian able to provide consent and child able to provide assent; for adults, ability to self-consent per MacArthur Competence Assessment Tool for Clinical Research
Ability to comply with study procedures
Treatment-seeking youth diagnosed with CUD as per the Mini-International Neuropsychiatric Interview (MINI-KID (Sheehan et al., 2010) for 15-17 years old and MINI (Sheehan et al., 1998) for 18-21 years old)
Cannabis use 3+ days per week (or 12+ days in the past month) as verified by Timeline Followback (TLFB) (Sobell \& Sobell, 1996)
Fluent in spoken English

Exclusion

Medical conditions contraindicated or associated with altered TMS risk profile, including history of intracranial pathology, intracranial lesions, epilepsy or seizure disorders, or individuals with a family history of epilepsy or seizure in a first degree relative, traumatic brain injury, brain tumor, stroke, neurocardiogenic syncope, mania/bipolar disorder, implanted medical devices or metallic objects in the head, current pregnancy or not using effective contraception if capable of becoming pregnant, or any other serious medical condition or contraindication as judged by the study physician; moderate to severe heart disease, pediatric populations with risk factors for neurocardiogenic syncope (history of syncope/presyncope related to noxious stimuli, anxiety, micturation, or posture)
Inability to undergo MRI.
Diagnosis of psychosis, cognitive disability or active suicidality. The MINI (Sheehan et al., 1998, 2010) will be used to assess current psychiatric comorbidities and the Ask Suicide-Screening Questions (ASQ) will be used to assess suicidality (Horowitz et al., 2012).
Primary current alcohol or substance use disorder, except for caffeine or nicotine.
Taking a medication with high seizurogenic potential (e.g., clomipramine, tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, anti-psychotics, lithium, bupropion -e.g. Wellbutrin). Participants taking psychotropic medications will be included if dose is stable for ≥4 weeks with no anticipated changes during the study period. All concurrent treatments will be monitored during the study period.
If an individual is currently taking antibiotics that affect the central nervous system such as Fluoroquinolones (Ciprofloxacin, Levofloxacin, Moxifloxacin) or Imipenem, medications that have the potential of lowering seizure threshold, participation in the study will be delayed until 5 days after the last antibiotic dose.
If an individual is taking antihistamines (i.e. Benadryl/diphenhydramine), they will be asked to refrain from using the antihistamine for at least 24 hours before the TMS session. If the participant is not able to do so, they will be excluded from the study.

What this trial measures

  • Feasibility, tolerability, and acceptability of rTMSMonth 4

    Daily side-effects reports on each intervention day and an exit interview will be collected.

  • rTMS effects on neural target engagementMonth 4

    Pre- and post-intervention resting connectivity fMRI data will be collected to examine changes in LDLPFC-cACC connectivity

  • Changes in CUD recovery metricsMonth 4

    Cannabis craving will be measured using a validated self-report scale. Cannabis use will be evaluated during in-person monthly visits across a 3-month follow-up period, using interviewer-administered assessments and urine toxicology. An optional component of the study will include daily smartphone-based brief surveys to remotely track self-reported cannabis craving and use in real time.